Publications by authors named "Tim Perren"

Claim this Profile
W
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Won Kim, Tim J Perren

Lancet Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
Chris Twelves, Sue Cheeseman, Will Sopwith, Matthew Thompson, Majid Riaz, Tim Perren

BMC Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Weon Kim, Tim Perren

Lancet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tim Perren

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy.
Sarah J Storr, Siwei Zhang, Tim Perren, Mark Lansdown, Hiba Fatayer

Oncotarget· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Renu Gahlaut, Aneliese Bennett, Hiba Fatayer, Barbara J Dall, Nisha Sharma, Tim Perren

Eur J Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, Gunnar Kristensen, Lorraine Elit, Tim Perren

Lancet Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Tim Perren

J Clin Oncol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis